Nasdaq · Consumer Discretionary
POMDOCTOR Ltd (POM)
As-reported financials and recent SEC filings for POMDOCTOR Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$399.9M
Net income
$-130.9M
Net margin
-32.7%
Diluted EPS
$-21.96
ROE
27.2%
P/E (TTM)
—
Market cap
—
Debt / equity
-0.2×
Income statement (as reported)
| Line | FY2025 | FY2025 | FY2025 |
|---|---|---|---|
| Revenue | $399.9M | $342.6M | $304.9M |
| Gross profit | $52.3M | $47.7M | $38.7M |
| Operating income | $-118.6M | $-25.8M | $-22.2M |
| Net income | $-130.9M | $-37.4M | $-36.9M |
| Diluted EPS | $-21.96 | $-22.72 | $-23.04 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-07-02
View on EDGAR →6-K2026-06-17
View on EDGAR →6-K2026-05-28
View on EDGAR →F-6 POS2026-05-28
View on EDGAR →6-K2026-05-14
View on EDGAR →20-F2026-05-14
View on EDGAR →32026-04-30
View on EDGAR →NT 20-F2026-04-30
View on EDGAR →Largest Consumer Discretionary peers
Go deeper on POM
Search POMDOCTOR Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.